Stem cells · Lesson 5 of 8 · 3 min

Where do MSCs come from? Tissue sources and autologous versus allogeneic cells

MSCs can be sourced from several tissues, from the patient or from a donor. The source and the processing shape both the product and how it is regulated.

A researcher looking into a microscope

Key takeaways.

  • MSC sources include bone marrow, adipose tissue, umbilical cord blood and tissue, dental pulp and placenta.
  • Adipose tissue yields the most MSCs per gram, roughly 100 to 500 times more than bone marrow.
  • Harvest, isolation and expansion each affect what cells are recovered and how they behave.
  • The autologous or allogeneic choice shapes the regulatory pathway and manufacturing logistics.
  • Culture-expanding MSCs moves most products into the FDA's Section 351 biological drug category.

Tissue sources

Mesenchymal stem/stromal cells (MSCs) have been sourced from several tissues. These include bone marrow, adipose tissue, umbilical cord blood, umbilical cord tissue (Wharton's Jelly), dental pulp, peripheral blood and placental tissue.

Yield differs by source. Adipose tissue, obtained through liposuction, yields the highest number of MSCs per gram of tissue. The course puts this at approximately 100 to 500 times more than bone marrow.

Processing changes the product

Each step from tissue to product affects the cells. How tissue is harvested affects what is recovered. Isolation methods determine purity and yield. Expansion conditions influence cell properties.

Storage matters too. Frozen cell products use DMSO (dimethyl sulfoxide) as a cryoprotectant. It prevents the formation of ice crystals, which can damage cell membranes during freezing.

Autologous versus allogeneic

Autologous cells come from the patient who will receive them. Allogeneic cells come from a donor. The course describes this choice as shaping everything from regulatory pathway to manufacturing logistics.

How source and processing meet regulation

The FDA treats culture expansion of MSCs as more than minimal manipulation. That places most expanded MSC products in the Section 351 category, which is regulated as a biological drug. There is a narrow exception for autologous cells removed and reimplanted during the same surgical procedure.

Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses that clinics market. The tissue source does not change that.

Educational content for healthcare professionals. Not a treatment recommendation. Stem cell therapies are not FDA-approved for the orthopaedic, pain and aesthetic uses most clinics offer.

Stem cells: 0 of 8 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Harvest and isolation methods
  • Expansion conditions and their effect on cells
  • How the main tissue sources compare in practice
  • Regulatory consequences of each sourcing choice

Common questions.

Which tissue yields the most MSCs?
Adipose tissue yields the highest number of MSCs per gram, approximately 100 to 500 times more than bone marrow according to the course material.
What is the difference between autologous and allogeneic cells?
Autologous cells come from the patient who receives them. Allogeneic cells come from a donor. The choice affects the regulatory pathway and manufacturing logistics.
Why is DMSO used when freezing cells?
DMSO is a cryoprotectant. It prevents ice crystals from forming and damaging cell membranes during freezing.

Sources

  • Matas J, Orrego M, Amenabar D, Infante C, Tapia-Limonchi R, Cadiz MI, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: A randomized double-blind placebo-controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504-13.
  • Pers YM, Rackwitz L, Ferreira R, Pullig O, Delfour C, Barry F, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: A phase I dose-escalation trial. Stem Cells Transl Med. 2016;5(7):847-56.
  • Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep. 2015;35(2):e00191.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.